Application Value of Yixinshu Tablets Combined with Trimetazidine in Pa-tients with Coronary Heart Disease and Angina Pectoris

SUN Junhua; YANG Mincong; FAN Yanbin

doi:10.3969/j.issn.1002-3429.2023.08.028

Abstract：Objective To investigate the application value of Yixinshu tablets combined with Trimetazidine in pa-tients with coronary heart disease(CHD)and angina pectoris based on the changes of serum serine protease inhibitor(Vaspin)level and Gensini score.Methods From April 2020 to April 2021,47 patients with CHD and angina pectoris who were treated with Yixinshu tablets combined with Trimetazidine were selected as the combination group,and 47 patients with CHD and angina pectoris treated with Trimetazidine during the same period were selected as the control group.The incidence of angina pectoris[frequency of attack,duration,visual analogue scale(VAS)score],TCM syndrome scores(chest tight-ness,chest pain,palpitation,shortness of breath,insomnia and dreaminess,cyanosis of the lips),hemorheological indexes[fibrinogen,plasma viscosity,whole blood viscosity],serum inflammatory factors[C-reactive protein(CRP),interleukin-27(IL-27),tumor necrosis factor α],serum Vaspin,Gensini scores,and the occurrence of adverse reactions during treatment were compared between the two groups before treatment and at 3 months after treatment.Results At 3 months after treat-ment,the frequency,duration,VAS score,TCM syndrome score,hemorheology index,serum inflammatory factor and Gensi-ni score of angina pectoris in the two groups were lower or shorter than those before treatment,and the VAS score,TCM syn-drome score,serum inflammatory factor and Gensini score of the combination group were lower than those of the control group.The serum Vaspin level in the two groups was higher than that before treatment,and higher in combination group than in con-trol group(P＜0.05).During treatment,the incidence of adverse reactions was 17.02%(8/47)in the combination group and 10.64%(5/47)in the control group,and there was no statistical significance between the two groups(P＞0.05).Con-clusion Yixinshu tablets combined with Trimetazidine is effective in the treatment of patients with CHD and angina pectoris,which can alleviate clinical symptoms,reduce serum inflammatory factors and Vaspin levels,regulate hemorheology,and im-prove the degree of coronary artery disease with good safety.